Biogen Settles False Claims Allegations for $900 Million; Relator To Receive Nearly $250 Million

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Biogen Settles False Claims Allegations for $900 Million; Relator To Receive Nearly $250 Million

Dennis Tosh

September 28, 2022 at 06:58 PM EST

The Cambridge, Mass.-based pharmaceutical manufacturer Biogen Inc. has agreed to pay $900 million to resolve allegations that by paying illegal kickbacks to physicians to induce them to prescribe its multiple sclerosis (MS) drugs, the company caused the submission of false reimbursement claims to Medicare and Medicaid (United States ex rel. Bawduniak v. Biogen Idec Inc., No. 1... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Biogen Settles False Claims Allegations for $900 Million; Relator To Receive Nearly $250 Million

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT